Cullinan Therapeutics, Inc.
Velinotamig
SLE
Countdown
177days
Phase 1 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 1 trial results for Velinotamig in SLE are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Initial multi-dose regimen data from the dose escalation phase in patients with SLE are expected to be shared in Q4 2026.”